scholarly journals Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft

2011 ◽  
Vol 47 (2) ◽  
pp. 277-282 ◽  
Author(s):  
J Hasskarl ◽  
A Zerweck ◽  
R Wäsch ◽  
G Ihorst ◽  
H Bertz ◽  
...  
Keyword(s):  
Allogeneic Pbsct ◽  
Donor Lymphocyte Infusions

scholarly journals Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis

2021 ◽  
Author(s):  
Andrés R. Rettig ◽  
Gabriele Ihorst ◽  
Hartmut Bertz ◽  
Michael Lübbert ◽  
Reinhard Marks ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myeloid Leukemia ◽  
Risk Marker ◽  
Single Center ◽  
Hematopoietic Stem ◽  
Acute Myeloid ◽  
Donor Lymphocyte Infusions

AbstractAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially curative for acute myeloid leukemia (AML). The inherent graft-versus-leukemia activity (GvL) may be optimized by donor lymphocyte infusions (DLI). Here we present our single-center experience of DLI use patterns and effectiveness, based on 342 consecutive adult patients receiving a first allo-HSCT for AML between 2009 and 2017. The median age at transplantation was 57 years (range 19–79), and the pre-transplant status was active disease in 58% and complete remission (CR) in 42% of cases. In a combined landmark analysis, patients in CR on day +30 and alive on day +100 were included. In this cohort (n=292), 93 patients received cryopreserved aliquots of peripheral blood-derived grafts for DLI (32%) and median survival was 55.7 months (2-year/5-year probability: 62%/49%). Median survival for patients receiving a first dose of DLI “preemptively,” in the absence of relapse and guided by risk marker monitoring (preDLI; n=42), or only after hematological relapse (relDLI; n=51) was 40.9 months (2-year/5-year: 64%/43%) vs 10.4 months (2-year/5-year: 26%/10%), respectively. Survival was inferior when preDLI was initiated at a time of genetic risk marker detection vs mixed chimerism or clinical risk only. Time to first-dose preDLI vs time to first-dose relDLI was similar, suggesting that early warning and intrinsically lower dynamics of AML recurrence may contribute to effectiveness of preDLI-modified GvL activity. Future refinements of the preemptive DLI concept will benefit from collaborative efforts to diagnose measurable residual disease more reliably across the heterogeneous genomic spectrum of AML.

scholarly journals Safety but Limited Efficacy of Unconditioned Donor Lymphocyte Infusions (DLI) in Patients Treated with Post-Transplantation Cyclophosphamide (PTCy) without Serotherapy

2021 ◽  
Vol 27 (3) ◽  
pp. S266-S267
Author(s):  
Scott Napier ◽  
Dimana Dimitrova ◽  
Meredith J. McAdams ◽  
Ronald E Gress ◽  
Jennifer A. Kanakry ◽  
...  
Keyword(s):  
Post Transplantation ◽  
Limited Efficacy ◽  
Donor Lymphocyte Infusions

scholarly journals Myeloablative conditioning with fludarabine and busulfan for allogeneic PBSCT in chronic phase CML

2005 ◽  
Vol 11 (2) ◽  
pp. 22
Author(s):  
M. Iravani ◽  
M. Tavakoli ◽  
A.R. Shamshiri ◽  
A. Mousavi ◽  
B. Bahar ◽  
...  
Keyword(s):  
Chronic Phase ◽  
Myeloablative Conditioning ◽  
Allogeneic Pbsct

Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions

2010 ◽  
Vol 38 (11) ◽  
pp. 1066-1073 ◽  
Author(s):  
Xinchao Wang ◽  
Anita Schmitt ◽  
Baoan Chen ◽  
Xun Xu ◽  
Jiju Mani ◽  
...  
Keyword(s):  
T Cells ◽  
Cd8 T Cells ◽  
Selection Of ◽  
Donor Lymphocyte Infusions
Sign in / Sign up

Export Citation Format

Share Document